Much to the delight, a bifunctional EZH2 inhibitor(EZH2-HDAC dual inhibitor) demonstrating anti-GBM efficacy was alsoreported that hampered epithelial-to-mesenchymal transition by increasingthe E-cadherin expression in GBM U87 cells.40 This evidence concerns the gene HDAC9 and glioblastoma.